Monsanto Company By Their Patent Agent, De Penning and Depen v. Coramandal Indag Products (P) Ltd.

In the high-stakes world of intellectual property, the line between a genuine invention and a repackaged idea can be razor thin. For one of the world's largest agrochemical companies, that line proved fatal. A patent that seemed to protect a breakthrough herbicide formulation was dismantled not by a competitor's superior technology, but by the simple truth that the world already knew what they claimed to have invented. This case stands as a powerful reminder that patents are not rewards for effort alone; they are rewards for genuine novelty.

Monsanto Company, a name synonymous with agricultural innovation, held patents covering herbicide formulations containing a chemical compound known as 'Butachlor.' These patents positioned Monsanto at the center of India's growing agrochemical market. Coramandal Indag Products (P) Ltd., an Indian company operating in the same space, found itself accused by Monsanto of infringing these patents. Rather than backing down, Coramandal Indag Products chose to fight back, arguing that the patents Monsanto wielded against them were fundamentally flawed. The dispute escalated all the way to the Supreme Court of India, where the validity of Monsanto's patents would be put under the microscope.

Monsanto entered the courtroom armed with patents they believed gave them exclusive rights over Butachlor-based herbicide formulations. Their position rested on the assumption that their specific formulation represented a protectable invention worthy of legal monopoly. Coramandal Indag Products, however, struck at the foundation of Monsanto's claims. They argued that the patents were liable to be revoked under various sections of the Patents Act, 1970. Their central contention was devastating in its simplicity: Butachlor was already publicly known before Monsanto's patent, and the process of emulsification used in the formulation was common knowledge within the relevant industry. In other words, Monsanto was not claiming a new invention; they were claiming ownership over something the public already possessed.

The Supreme Court sided with Coramandal Indag Products. After examining the evidence and the arguments, the Court concluded that Butachlor was publicly known prior to Monsanto's patent claims, and that the emulsification process at the heart of the formulation was common knowledge. Because the invention lacked the novelty required under the Patents Act, 1970, the patent could not stand. The Court revoked Monsanto's patent, delivering a decisive victory to the defendant and stripping the multinational of its claimed monopoly over the herbicide formulation.

For founders and IP professionals, this case delivers a sobering lesson: a patent is only as strong as the novelty behind it. Before investing heavily in patent prosecution or enforcement, rigorously investigate whether your invention truly stands apart from what is already publicly known or commonly used in your industry. Public knowledge does not require widespread consumer awareness; if experts, practitioners, or published materials already disclose the substance or process, your patent may be vulnerable to revocation. Build on genuine innovation, not on repackaging what the world already knows.